InVivo Biosystems

Executive Summary

InVivo Biosystems is a preclinical biotechnology company that leverages an AI-powered platform combined with whole-organism models (zebrafish and C. elegans) to accelerate target validation and drug development. By integrating advanced genetics and AI-driven analytics, the company aims to address the inefficiencies in the traditional drug discovery pipeline, reducing the time and cost from target identification to therapeutic candidate. Their approach enables scalable, decision-ready data that can de-risk drug programs at an early stage. Founded in 2014 and headquartered in Eugene, Oregon, InVivo is positioned at the intersection of AI, genomics, and CRISPR technologies. The company operates in the preclinical stage, focusing on providing services and data to biopharma partners. With the growing adoption of AI in drug discovery and the increasing need for more predictive preclinical models, InVivo's platform could offer a competitive advantage. However, as a private company with undisclosed funding and valuation, its near-term visibility is limited. Key upcoming catalysts include potential funding rounds, strategic partnerships, and validation of their platform through external studies or collaborations.

Upcoming Catalysts (preview)

• Q4 2026Series A Funding Announcement70% success
• TBDMajor Pharmaceutical Partnership60% success
• Q3 2026Preclinical Data Presentation at Major Conference80% success